"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thiohydantoin benzene derivative.
MeSH Number(s)
D03.383.129.308.432.555.868.650
Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".
Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".
This graph shows the total number of publications written about "Phenylthiohydantoin" by people in Harvard Catalyst Profiles by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 5 | 6 |
| 2014 | 5 | 3 | 8 |
| 2015 | 5 | 2 | 7 |
| 2016 | 4 | 4 | 8 |
| 2017 | 9 | 5 | 14 |
| 2018 | 5 | 6 | 11 |
| 2019 | 7 | 6 | 13 |
| 2020 | 2 | 7 | 9 |
| 2021 | 7 | 5 | 12 |
| 2022 | 0 | 6 | 6 |
Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.
-
Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 12 20; 40(36):4278-4279.
-
Cardiovascular and Metabolic Diagnoses Associated With Novel Hormonal Agents for Prostate Cancer in Nontrial Populations. J Natl Cancer Inst. 2022 08 08; 114(8):1057-1058.
-
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. J Natl Cancer Inst. 2022 08 08; 114(8):1127-1134.
-
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 06 01; 28(11):2237-2247.
-
Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. JNCI Cancer Spectr. 2022 03 02; 6(2).
-
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clin Cancer Res. 2022 Mar 01; 28(5):860-869.
-
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar; 18(10):1185-1198.
-
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022 01; 28(1):144-153.
-
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem. 2022 02; 298(2):101556.
-
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.